Form 4: Tvardi CFO Granted 17,500 Stock Options

Tvardi Therapeutics' Chief Financial Officer, Avi Daniel Conn, was granted 17,500 employee stock options with a $4.2 exercise price, vesting over four years.

Summary

• Avi Daniel Conn, Chief Financial Officer of Tvardi Therapeutics, Inc. (TVRD), was granted 17,500 employee stock options.
• The options have an exercise price of $4.2 per share.
• The transaction date for this grant was December 16, 2025.
• The options will vest over a period of four years: 25% on December 16, 2026, and the remaining balance in equal monthly installments over the subsequent 36 months.
• Vesting is contingent upon Mr. Conn's continuous service to the company.
• The options expire on December 16, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned contract or instruction.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a neutral to slightly positive event, as it aligns management incentives with shareholder interests, but does not directly reflect operational performance or financial results.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options were granted at an exercise price of $4.2, providing a clear benchmark for future stock performance to realize value.

Future Outlook

The future outlook for the Chief Financial Officer's equity compensation is tied to the company's stock performance relative to the $4.2 exercise price and his continuous service through the vesting schedule, which extends over the next four years.

Industry Context

The grant of employee stock options is a standard practice in the biotechnology and pharmaceutical industries, particularly for executive compensation, to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success and shareholder value creation of the company.

Stakeholder Impact

• Shareholders: The grant of options to the CFO can align his interests with shareholders, potentially leading to decisions that enhance long-term stock value. However, it also represents potential future dilution if options are exercised.
• Employees: This grant is part of the executive compensation structure, which can influence overall compensation philosophy within the company.

Next Steps

• The initial 25% of the options will vest on December 16, 2026.
• The remaining options will vest in equal monthly installments over the subsequent 36 months, subject to continuous service.

Key Dates

Keywords

Tvardi Therapeutics, TVRD, Stock Options, Employee Stock Option, CFO, Insider Transaction, Form 4, Equity Compensation, Vesting Schedule, Rule 10b5-1